pharma

Dr. Reddy's Laboratories

DRREDDY · Nifty 50

1,269

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

ValuationPE 24.8 (50%ile of 5Y range 15-118). Trading near median.
Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score90/100 (STRONG). 0 positive flags, 2 concerns.
Historical Context189 similar technical setups. Average outcome: -7.9% decline. 0% positive.
Revenue TrendRevenue declining at -11.6% YoY. Revenue declining — -11.6% YoY

Fundamental

90/100

STRONG

Trust

95/100

Verification

Coverage

89/100

HIGH

Quick Take

Dr. Reddy's Laboratories scores 90/100 on fundamentals (strong). Dr. Reddy's Laboratories: PE above historical average. BROAD EXPANSION regime.

Fundamental Score: 90/100 · STRONG · 1 signals detected

DuPont Analysis

ROE 11.4% broken into three drivers. Each shows how efficiently the company generates returns.

ROE11.4%=
12.8%Net Margin
×
0.6xTurnover
×
1.5xLeverage

ROE of 11.37% is moderate margin-driven and stable. Net margin of 12.8% × asset turnover of 0.58x × leverage of 1.5x.

What This Means

Net margin of 12.8% means the company keeps ₹12.8 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.58x means the company efficiently uses its assets to generate revenue. Leverage of 1.5x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

55.5%

Operating

17.4%

Net

12.8%

declining

Gross margin 55.5% → operating margin 17.4% → net margin 12.8%. Margins are DECLINING. Check if input costs are rising or competition is pressuring pricing.

Financial Health

Earnings Quality

ADEQUATE

Cash flow covers net income 1.3x — earnings are ADEQUATE quality. Cash conversion is reasonable.

Debt Sustainability

COMFORTABLE

Interest covered 15.7x — very comfortable. Debt service is not a concern. Debt/EBITDA at 1.0x is low — balance sheet has capacity.

Free Cash Flow

STRONG

FCF margin at 5.5% — moderate. Generating cash after investments.

Peer Comparison

Dr. Reddy's Laboratories is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹1332 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹1206 (-5%)

Further downside risk

🟡

PE reverts to 5Y median of 23.4

Valuation normalization

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

➡️ Leverage Slowly Rising: Debt growing faster (65.4%) than equity (13.1%)

Risk Flags

🔴 1 Critical⚠️ 1 Warning2 total flags
🔴Cash covers only 9% of current liabilities
Balance Sheet

Liquidity squeeze. Company may struggle to meet short-term obligations without refinancing.

⚠️81% of debt is short-term
Balance Sheet

High refinancing risk. Company needs to roll over debt frequently. Vulnerable to credit market freezes.

⚠️ 1 critical + 1 warning flags. Exercise caution.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
Our margin analysis (declining) matches news reports of cost/margin pressure

50 articles scanned for fundamental themes

Facts

P/E Ratio
24.8HIGH
P/B Ratio
2.8HIGH
ROE
11.8%HIGH
Market Cap
₹10620300.2L CrHIGH
From 52W High
92% of high
Promoter Holding
29.8%MODERATE
Institutional
53.7%
Sector Peers
10
Dr. Reddy's Laboratories Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight